Head-to-head evidence
CT-P13 vs CT-P17
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
CT-P13 · Inflectra / Remsima
Marketed by Celltrion
NCT01217086 · Phase 3 · completed
The study was randomized, double-blind, and actively controlled with Remicade in 617 participants. However, its primary endpoint was pharmacokinetic equivalence, a surrogate measure, and the registry does not report whether the equivalence comparison was met.
CT-P17
Developed by Celltrion
NCT03789292 · Phase 3 · completed
The trial was a large randomized, quadruple-blind comparison of CT-P17 and Humira, with 324 participants per initial treatment group. Its primary clinical endpoint, ACR20 response at Week 24, had identical reported counts in both groups, but the registry does not state whether the prespecified statistical comparison met its criterion, so the result is unclear.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CT-P13's landscape · CT-P17's landscape